<html>
<head><title>
Prepared and filed by St Ives Financial
</title>
</head>
<body bgcolor="#FFFFFF">
<div style="page-break-before:always"></div>
<page>
<p align="center"><font size="2" face="serif">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br>WASHINGTON, D.C. 20549</font></p>
<hr width="150" size=1 noshade>

<p align="center"><font size="2" face="serif">FORM 8-K</font></p>
<p align="center"><font size="2" face="serif">CURRENT REPORT<br>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></p>
<p align="center"><font size="2" face="serif">Date of Report (Date of earliest event reported):  October 5, 2005</font></p>
<table width="100%" border="0" align="center" cellpadding="0" cellspacing="0">
<tr valign="top">
<td align="center"><font size="2" face="serif">Savient Pharmaceuticals, Inc.</font></td>
</tr>
<tr valign="top">
  <td align="center"><hr size="1" noshade>
    </td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">(Exact Name of Registrant as Specified in Charter)</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top" bgcolor="#ffffff">
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="center">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td width="32%" align="center"><font size="2" face="serif">Delaware</font></td>
<td align="left" width="2%">&nbsp;</td>
<td width="32%" align="center"><font size="2" face="serif">0-15313</font></td>
<td width="2%" align="left">&nbsp;</td>
<td width="32%" align="center"><font size="2" face="serif">13-3033811</font></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
  <td colspan="5" align="center"><hr size="1" noshade>
    </td>
  </tr>
<tr valign="top" bgcolor="#FFFFFF">
<td width="32%" align="center"><font size="2" face="serif">(State or Other Juris-<br>
  diction of Incorporation</font></td>
<td width="2%" align="left">&nbsp;</td>
<td width="32%" align="center"><font size="2" face="serif">(Commission<br>
  File Number)</font></td>
<td width="2%" align="left">&nbsp;</td>
<td width="32%" align="center"><font size="2" face="serif">(IRS Employer<br>
  Identification No.)</font></td>
</tr>
</table>
<table width="100%" border="0" align="center" cellpadding="0" cellspacing="0">
<tr valign="top">
  <td align="center">&nbsp;</td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">One Tower Center, 14th Floor<br>East Brunswick, New Jersey 08816</font></td>
</tr>
<tr valign="top">
  <td align="center"><hr size="1" noshade>
    </td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">(Address of Principal Executive Offices) (Zip Code)</font></td>
</tr>
</table>
<p align="center"><font size="2" face="serif">Registrant&#146;s telephone number, including area code:  (732) 418-9300</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top"> <td align="left"><hr size="1" noshade>
    </td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">(Former Name or Former Address, if Changed Since Last Report)</font></td>
</tr>
</table>
<div style="text-indent: 3%">
  <p align="left"><font size="2" face="serif">Check the appropriate box below
      if the Form 8-K filing is intended to simultaneously satisfy the filing
      obligation of the registrant under any of the following provisions (<i>see</i> General
      Instruction A.2. below):</font></p>
  <p align="left"><font size="2" face="serif"><img src="emptybox.gif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p>
  <p align="left"><font size="2" face="serif"><img src="emptybox.gif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
  <p align="left"><font size="2" face="serif"><img src="emptybox.gif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font></p>
  <p align="left"><font size="2" face="serif"><img src="emptybox.gif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font></p>
</div>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="left"><font size="2" face="serif"><b>Item 5.02. Departure of Directors
      or Principal Officers; Election of Directors; Appointment of Principal
      Officers</b></font></p>
  <p align="left"><font size="2" face="serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On
      October 5, 2005, Lawrence A. Gyenes resigned as Senior Vice President,
      Chief Financial Officer and Treasurer of Savient Pharmaceuticals, Inc.
      (the &#147;Company&#148;).</font></p>
  <p align="left"><font size="2" face="serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On
      October 5, 2005, Gina Gutzeit, age 44, was appointed Interim Chief Financial
      Officer of the Company.</font></p>
<div style="text-indent: 3%">
  <p align="left"><font size="2" face="serif">Since September 2002, Ms. Gutzeit
      has been a senior managing director with FTI Palladium Partners, the interim
      management practice of FTI Consulting, Inc., a corporate finance consulting
      firm. From July 2000 to August 2002, Ms. Gutzeit was a partner in the Financial
      Advisory Services practice of PricewaterhouseCoopers LLP.</font></p>
  <p align="left"><font size="2" face="serif">The full text of the press release
      issued in connection with the resignation of Mr. Gyenes and the appointment
      of Ms. Gutzeit is furnished as Exhibit 99.1 to this Current Report on Form
      8-K.</font></p>
</div>
<p align="left"><font size="2" face="serif"><b>Item 9.01. Financial Statements
      And Exhibits</b></font></p>
<div style="text-indent: 3%">
  <p align="left"><font size="2" face="serif">(d) Exhibits</font></p>
</div>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top" bgcolor="#ffffff">
<td width="3%" align="left"></td>
<td width="3%" align="left"><font size="2" face="serif">99.1</font></td>
<td width="2%" align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Press release dated October 5, 2005</font></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
  <td align="left"></td>
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
</table>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="center"><font size="2" face="serif">SIGNATURE</font></p>
<p align="left"><font size="2" face="serif">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>  <table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top"> <td width="49%" align="left"><font size="1" face="serif">&nbsp;</font></td>
  <td width="2%" align="left">&nbsp;</td>
  <td colspan="2" align="left"><font size="2" face="serif">SAVIENT PHARMACEUTICALS, INC.</font></td>
</tr>
<tr valign="top">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="left"></td>
</tr>
<tr valign="top">
<td align="left" width="49%"><font size="2" face="serif">Date:  October 12, 2005</font></td>
<td align="left" width="2%">&nbsp;</td>
<td align="left" width="3%"><font size="2" face="serif">By:</font></td>
<td align="left"><font size="2" face="serif">/s/ Philip K. Yachmetz</font></td>
</tr>
<tr valign="top">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="left"><hr size="1" noshade>
    </td>
</tr>
<tr valign="top">
<td width="49%" align="left"><font size="2" face="serif">&nbsp;</font></td>
<td width="2%" align="left">&nbsp;</td>
<td width="3%" align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">Philip K. Yachmetz<br>Senior Vice President, General Counsel and Secretary</font></td>
</tr>
<tr valign="top">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
</table>
<hr noshade align="center" width="100%" size="2">
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "b409238_8k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 8607}]
{"company-data": {"conformed-name": "SAVIENT PHARMACEUTICALS INC", "cik": "0000722104", "assigned-sic": "2833", "irs-number": "133033811", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-15313", "film-number": "051134729"}, "business-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816", "phone": "7324189300"}, "mail-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816"}, "former-company": {"former-conformed-name": "BIO TECHNOLOGY GENERAL CORP", "date-changed": "19920703"}}
Prepared and filed by St Ives Financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  October 5, 2005
Savient Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
0-15313
13-3033811
(State or Other Juris-
diction of Incorporation
(Commission
File Number)
(IRS Employer
Identification No.)
One Tower Center, 14th Floor
East Brunswick, New Jersey 08816
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code:  (732) 418-9300
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
      if the Form 8-K filing is intended to simultaneously satisfy the filing
      obligation of the registrant under any of the following provisions (
see
General
      Instruction A.2. below):
Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))
Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))
Item 5.02. Departure of Directors
      or Principal Officers; Election of Directors; Appointment of Principal
      Officers
(b)      On
      October 5, 2005, Lawrence A. Gyenes resigned as Senior Vice President,
      Chief Financial Officer and Treasurer of Savient Pharmaceuticals, Inc.
      (the "Company").
(c)      On
      October 5, 2005, Gina Gutzeit, age 44, was appointed Interim Chief Financial
      Officer of the Company.
Since September 2002, Ms. Gutzeit
      has been a senior managing director with FTI Palladium Partners, the interim
      management practice of FTI Consulting, Inc., a corporate finance consulting
      firm. From July 2000 to August 2002, Ms. Gutzeit was a partner in the Financial
      Advisory Services practice of PricewaterhouseCoopers LLP.
The full text of the press release
      issued in connection with the resignation of Mr. Gyenes and the appointment
      of Ms. Gutzeit is furnished as Exhibit 99.1 to this Current Report on Form
      8-K.
Item 9.01. Financial Statements
      And Exhibits
(d) Exhibits
99.1
Press release dated October 5, 2005
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SAVIENT PHARMACEUTICALS, INC.
Date:  October 12, 2005
By:
/s/ Philip K. Yachmetz
Philip K. Yachmetz
Senior Vice President, General Counsel and Secretary